FX 2149

Overview

FX 2149 is a blood-brain barrier-permeable LRRK2 inhibitor. FX 2149 inhibits the GTP-binding activity of LRRK2 , reduces the kinase activity of LRRK2 , and attenuates LPS ( HY-D1056 )-induced upregulation of LRRK2 . FX 2149 alleviates mutant LRRK2-induced neurodegeneration, microglial activation, static aggregation of mitochondria and lysosomes, reduces apoptosis , and improves mitochondrial and lysosomal motility deficits in neurites. FX 2149 can be used in research related to Parkinson's disease.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > LRRK2 | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-169900
• CAS No.: 1842427-90-0
• Molecular Formula: C15H17N3O3S
• Molecular Weight: 319.38
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source